The approach to treating patients with pneumonia generally involves:
Whether patients are treated at home or admitted to the hospital, receiving their first dose of antibiotics quickly improves the outcome of the illness and the speed at which they get better.
Studies indicate that many patients do not need to be hospitalized for pneumonia, and can be safely treated at home. Likewise, many patients who are admitted to the hospital could be released sooner. A number of strategies are being devised to determine which patients can be safely discharged and when they can be discharged. Studies have shown that low-risk patients with mild-to-moderate pneumonia do just as well when treated as outpatients. They return to work and normal activities faster than those treated in the hospital.
A variety of guidelines and tools have been developed to help determine who can safely be treated at home and who cannot. One commonly used tool is called the Pneumonia Severity Index. All of these assessment tools are looking for risk factors. The more of these risk factors that are present, the less likely that the patient can be safely treated at home. Several of these risk factors determine a specific score. All of them must be used along with the doctor's clinical judgment.
Some of the important factors used to make a decision include:
Demographics.
Other Medical Illnesses. Patients may be considered at greater risk if they have:
Findings on a Physical Exam. Concerning findings include:
Laboratory and X-ray Findings. Laboratory findings that are of concern include:
Patients with very few of these risks often can be discharged with outpatient care only. This determination can often be made with a simple physical examination and history. Sometimes a patient only needs to be hospitalized for 24 hours for observation.
Patients with higher scores on these assessment tests often have many risk factors and usually are hospitalized.
When possible, treatment of community-acquired pneumonia should be started within 4 hours of admission to the emergency room or hospital to reduce the chances of mortality and decrease the amount of time a patient needs to spend in the hospital.
Home care may be possible, even in severe cases, when there is good support and available home nursing services. Often, caregivers can even be trained to administer intravenous antibiotics and chest therapy to patients at home.
The following tips are suggested:
Treatment. If the pneumonia is severe enough for hospitalization, the standard treatment is intravenous antibiotics for 5 - 8 days. In cases of uncomplicated pneumonia, many patients may need only 2 or 3 days of intravenous antibiotics followed by oral therapy. Antibiotics taken by mouth are prescribed when the patient has improved substantially or leaves the hospital.
ITSA/ATS guidelines recommend that patients admitted to the hospital (but not the ICU) be treated with fluoroquinolones or a beta-lactam plus a macrolide (preferably cefotaxime or ceftriaxone and ampicillin).
Duration of Stay. Patients should remain in the hospital until all their vital signs are stable. Most patients become stabilized in 3 days. Many experts use seven variables to measure stability and to determine whether the patient can go home:
Patients or their families should discuss these criteria with their doctor.
Chest therapy using incentive spirometry, rhythmic inhalation and coughing, and chest tapping are all important techniques to loosen the mucus and move it out of the lungs. It should be used both in the hospital and during recovery at home.
Incentive Spirometry. The patient uses an incentive spirometer at regular intervals to improve breathing and loosen sputum. The spirometer is a hand-held clear plastic device that includes a breathing tube and a container with a movable gauge. The patient exhales and then inhales forcefully through the tube, using the pressure of the inhalation to raise the gauge to the highest level possible.
Rhythmic Breathing and Coughing. During recovery, the patient performs rhythmic breathing and coughing every 4 hours:
American Academy of Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents -- United States, 2008. Pediatrics. 2008;121:219-220.
Barr CE, Schulman K, Iacuzio D, Bradley JS. Effect of oseltamivir on the risk of pneumonia and use of health care services in chidlren with clinically diagnosed influenza. Curr Med Res Opin. 2007;23(3):523-531.
Galobardes B, McCarron P, Jeffreys M, Davey-Smith G. Medical history of respiratory disease in early life relates to morbidity and mortality in adulthood. Thorax. 2008;Epub.
Gleason PP, Shaughnessy AF. STEPS new drug reviews telithromycin (Ketek) for treatment of community-acquired pneumonia. Am Fam Physician. 2007;76.
Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
Grijalva CG, et al. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine -- United States, 1997 - 2006. MMWR. 2009;58:1-4.
Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180:48-58.
Jackson M, Nelson JC, Weiss NS, Neuzil KM, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: A population-based, nested case-control study. Lancet. 2008;372:352-354.
Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccine in hospitalized adults with community-acquired pneumonia. Arch Intern Med. 2007;167:1938-1943.
Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661-666.
Kollef MH, Afessa B, Anzueto A, Veremakis C, Kerr KM, Margolis BD, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: The NASCENT randomized trial. JAMA. 2008;300:805-813.
Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med. 2007;22(1):62-67.
Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med. 2007;120:783-790.
Limper AH. Overview of Pneumonia. In: Goldman L, Ausiello D. Goldman: Cecil Medicine. Philadelphia, Pa: Saunders; 2007:chap 97.
Lutfiyya MN, Henley E, Chang LF. Diagnosis and treatment of community-acquired pneumonia. Am Fam Physician. 2006;73:442-450.
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27-S72.
Meissner HC, Long SS. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112:1447-1452.
Muller B, Harbath S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.
Neuman MI, Willett WC, Curhan GC. Vitamin and micronutrient intake and the risk of community-acquired pneumonia in US women. Am J Med. 2007;120:330-336.
Nisar N, Guleria R, Kuman S, Chand Chawla T, Ranjan Biswas N. Mycoplasma pneumoniae and its role in asthma. Postgrad Med J. 2007;83:100-104.
Reade MC, Yende S, DAngelo G, Milbrandt EB, Kellum JA, Bamato AE, et al. Sex disparities in treatment and outcome of community-acquired pneumonia. Am J Respir Crit Care Med. 2008;177:A770.
Sing S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: A meta-analysis. Arch Intern Med. 2009;169:219-229.
Spaude KA, Abrutyn E, Kirchner C, Kim A, Daley J, Fisman DN. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 2007;167(1):53-59.
Venditti M, Falcone M, Corrao S, Licata G, Serra P. Outcomes of patients hospitalized with community-acquired, health-care associated, and hospital-acquired pneumonia. Ann Intern Med. 2009;150:19-26.